

# Nicole DÃ©glon

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9324463/publications.pdf>

Version: 2024-02-01

176  
papers

13,238  
citations

15504

65  
h-index

24258

110  
g-index

184  
all docs

184  
docs citations

184  
times ranked

12630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Thrombolysis by PLAT/tPA increases serum free IGF1 leading to a decrease of deleterious autophagy following brain ischemia. <i>Autophagy</i> , 2022, 18, 1297-1317.	9.1	14
2	Extracellular vesicles: Major actors of heterogeneity in tau spreading among human tauopathies. <i>Molecular Therapy</i> , 2022, 30, 782-797.	8.2	17
3	Maximizing lentiviral vector gene transfer in the CNS. <i>Gene Therapy</i> , 2021, 28, 75-88.	4.5	15
4	Mitochondrial biogenesis in developing astrocytes regulates astrocyte maturation and synapse formation. <i>Cell Reports</i> , 2021, 35, 108952.	6.4	55
5	Lactate transporters in the rat barrel cortex sustain whisker-dependent BOLD fMRI signal and behavioral performance. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	18
6	Dysfunction of homeostatic control of dopamine by astrocytes in the developing prefrontal cortex leads to cognitive impairments. <i>Molecular Psychiatry</i> , 2020, 25, 732-749.	7.9	71
7	The C-terminal domain of LRRK2 with the G2019S mutation is sufficient to produce neurodegeneration of dopaminergic neurons in vivo. <i>Neurobiology of Disease</i> , 2020, 134, 104614.	4.4	15
8	Genome Editing for CNS Disorders. <i>Frontiers in Neuroscience</i> , 2020, 14, 579062.	2.8	18
9	Tau accumulation in astrocytes of the dentate gyrus induces neuronal dysfunction and memory deficits in Alzheimer's disease. <i>Nature Neuroscience</i> , 2020, 23, 1567-1579.	14.8	121
10	Lentiviral mediated RPE65 gene transfer in healthy hiPSCs-derived retinal pigment epithelial cells markedly increased RPE65 mRNA, but modestly protein level. <i>Scientific Reports</i> , 2020, 10, 8890.	3.3	5
11	Efficacy of THN201, a Combination of Donepezil and Mefloquine, to Reverse Neurocognitive Deficits in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2020, 14, 563.	2.8	14
12	Glucose metabolism links astroglial mitochondria to cannabinoid effects. <i>Nature</i> , 2020, 583, 603-608.	27.8	169
13	Genetic and pharmacological inactivation of astroglial connexin 43 differentially influences the acute response of antidepressant and anxiolytic drugs. <i>Acta Physiologica</i> , 2020, 229, e13440.	3.8	24
14	Emerging technologies to study glial cells. <i>Glia</i> , 2020, 68, 1692-1728.	4.9	32
15	Development of Efficient AAV2/DJ-Based Viral Vectors to Selectively Downregulate the Expression of Neuronal or Astrocytic Target Proteins in the Rat Central Nervous System. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 201.	2.9	13
16	P.2.10 Hippocampal Cx43 hemichannel inactivation protects from glutamatergic stress-related behaviour. <i>European Neuropsychopharmacology</i> , 2019, 29, S661-S662.	0.7	0
17	Cell-Type-Specific Gene Expression Profiling in Adult Mouse Brain Reveals Normal and Disease-State Signatures. <i>Cell Reports</i> , 2019, 26, 2477-2493.e9.	6.4	55
18	A New Tool for In Vivo Study of Astrocyte Connexin 43 in Brain. <i>Scientific Reports</i> , 2019, 9, 18292.	3.3	13

#	ARTICLE	IF	CITATIONS
19	Scalable Production of AAV Vectors in Orbitally Shaken HEK293 Cells. <i>Molecular Therapy - Methods and Clinical Development</i> , 2019, 13, 14-26.	4.1	45
20	Environment-dependent striatal gene expression in the BACHD rat model for Huntington disease. <i>Scientific Reports</i> , 2018, 8, 5803.	3.3	10
21	The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin. <i>Brain</i> , 2018, 141, 1434-1454.	7.6	23
22	Î²APP Processing Drives Gradual Tau Pathology in an Age-Dependent Amyloid Rat Model of Alzheimer's Disease. <i>Cerebral Cortex</i> , 2018, 28, 3976-3993.	2.9	13
23	IO7...Allele specific gene editing for huntington's disease mediated by the KAMICAS9 self-inactivating CRISPR/CAS9 system. , 2018, , .		0
24	Different tau species lead to heterogeneous tau pathology propagation and misfolding. <i>Acta Neuropathologica Communications</i> , 2018, 6, 132.	5.2	72
25	Scalable Production and Purification of Adeno-Associated Viral Vectors (AAV). <i>Methods in Molecular Biology</i> , 2018, 1850, 259-274.	0.9	3
26	Human Induced Pluripotent Stem Cell-Derived Astrocytes Are Differentially Activated by Multiple Sclerosis-Associated Cytokines. <i>Stem Cell Reports</i> , 2018, 11, 1199-1210.	4.8	114
27	CRISPR/Cas9-Mediated Genome Editing for Huntington's Disease. <i>Methods in Molecular Biology</i> , 2018, 1780, 463-481.	0.9	17
28	Huntingtin Aggregation Impairs Autophagy, Leading to Argonaute-2 Accumulation and Global MicroRNA Dysregulation. <i>Cell Reports</i> , 2018, 24, 1397-1406.	6.4	66
29	Therapeutic efficacy of regulable GDNF expression for Huntington's and Parkinson's disease by a high-induction, background-free "GeneSwitch" vector. <i>Experimental Neurology</i> , 2018, 309, 79-90.	4.1	21
30	B04...Environment-dependent modulation of striatal gene expression in the BACHD RAT model. , 2018, , .		0
31	A40...Modulation of DARPP32 homeostasis by htt protein in derivatives of disease-specific and control human pluripotent stem cells. , 2018, , .		0
32	Preclinical Evaluation of a Lentiviral Vector for Huntingtin Silencing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2017, 5, 259-276.	4.1	13
33	Formation of hippocampal mHTT aggregates leads to impaired spatial memory, hippocampal activation and adult neurogenesis. <i>Neurobiology of Disease</i> , 2017, 102, 105-112.	4.4	8
34	The Self-Inactivating KamiCas9 System for the Editing of CNS Disease Genes. <i>Cell Reports</i> , 2017, 20, 2980-2991.	6.4	96
35	AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington's disease. <i>Gene Therapy</i> , 2017, 24, 630-639.	4.5	69
36	[O3...04...01]: TAU SPREADING: HOW ARE TAU ASSEMBLIES TRANSFERRED FROM CELL TO CELL?. <i>Alzheimer's and Dementia</i> , 2017, 13, P906.	0.8	0

#	ARTICLE	IF	CITATIONS
37	Coupling of D2R Short but not D2R Long receptor isoform to the Rho/ROCK signaling pathway renders striatal neurons vulnerable to mutant huntingtin. <i>European Journal of Neuroscience</i> , 2017, 45, 198-206.	2.6	5
38	From huntingtin gene to Huntington's disease-altering strategies. , 2017, , 251-276.		0
39	A neuronal MCT2 knockdown in the rat somatosensory cortex reduces both the NMR lactate signal and the BOLD response during whisker stimulation. <i>PLoS ONE</i> , 2017, 12, e0174990.	2.5	42
40	Dominant-Negative Effects of Adult-Onset Huntingtin Mutations Alter the Division of Human Embryonic Stem Cells-Derived Neural Cells. <i>PLoS ONE</i> , 2016, 11, e0148680.	2.5	22
41	L5...Pre-clinical evaluation of aav5-mihtt gene therapy of huntington's disease in rodents. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A91.3-A92.	1.9	0
42	463. Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors for the Production of Adeno-Associated Virus Vectors. <i>Molecular Therapy</i> , 2016, 24, S183-S184.	8.2	1
43	327. Genetic Editing for Huntington's Disease. <i>Molecular Therapy</i> , 2016, 24, S131.	8.2	0
44	Adeno-associated virus and lentivirus vectors: a refined toolkit for the central nervous system. <i>Current Opinion in Virology</i> , 2016, 21, 61-66.	5.4	26
45	Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington's disease. <i>Glia</i> , 2016, 64, 1841-1856.	4.9	37
46	L4...Sustained and strong HTT silencing by AAV5-miHTT as therapy for huntington's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, A91.2-A91.	1.9	0
47	Alzheimer's disease-like APP processing in wild-type mice identifies synaptic defects as initial steps of disease progression. <i>Molecular Neurodegeneration</i> , 2016, 11, 5.	10.8	37
48	AMPK activation protects from neuronal dysfunction and vulnerability across nematode, cellular and mouse models of Huntington's disease. <i>Human Molecular Genetics</i> , 2016, 25, 1043-1058.	2.9	87
49	465. Transient Production of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Therapy Applications Using Suspension-Adapted HEK 293 Cells in Orbital Shaken Bioreactors. <i>Molecular Therapy</i> , 2015, 23, S184-S185.	8.2	0
50	O1-06-04: Non-human primate model of tauopathy. , 2015, 11, P138-P139.		0
51	Attenuated Levels of Hippocampal Connexin 43 and its Phosphorylation Correlate with Antidepressant- and Anxiolytic-Like Activities in Mice. <i>Frontiers in Cellular Neuroscience</i> , 2015, 9, 490.	3.7	58
52	Microtubule-associated protein 6 mediates neuronal connectivity through Semaphorin 3E-dependent signalling for axonal growth. <i>Nature Communications</i> , 2015, 6, 7246.	12.8	57
53	P1-037: Gene transfer of both app and ps1 induces hippocampal impairments close to human early phases of Alzheimer's disease. , 2015, 11, P351-P352.		0
54	The JAK/STAT3 Pathway Is a Common Inducer of Astrocyte Reactivity in Alzheimer's and Huntington's Diseases. <i>Journal of Neuroscience</i> , 2015, 35, 2817-2829.	3.6	221

#	ARTICLE	IF	CITATIONS
55	The striatal long noncoding RNA Abhd11os is neuroprotective against an N-terminal fragment of mutant huntingtin in vivo. <i>Neurobiology of Aging</i> , 2015, 36, 1601.e7-1601.e16.	3.1	34
56	Gene transfer engineering for astrocyte-specific silencing in the CNS. <i>Gene Therapy</i> , 2015, 22, 830-839.	4.5	20
57	Loss of the thyroid hormone-binding protein Crym renders striatal neurons more vulnerable to mutant huntingtin in Huntington's disease. <i>Human Molecular Genetics</i> , 2015, 24, 1563-1573.	2.9	25
58	Allele-Specific Silencing of Mutant Huntingtin in Rodent Brain and Human Stem Cells. <i>PLoS ONE</i> , 2014, 9, e99341.	2.5	45
59	Connexin 30 sets synaptic strength by controlling astroglial synapse invasion. <i>Nature Neuroscience</i> , 2014, 17, 549-558.	14.8	269
60	Neuron-to-neuron wild-type Tau protein transfer through a trans-synaptic mechanism: relevance to sporadic tauopathies. <i>Acta Neuropathologica Communications</i> , 2014, 2, 14.	5.2	203
61	SET translocation is associated with increase in caspase cleaved amyloid precursor protein in CA1 of Alzheimer and Down syndrome patients. <i>Neurobiology of Aging</i> , 2014, 35, 958-968.	3.1	14
62	P1-031: AMYLOID CASCADE INDUCTION IN AN AAV-BASED MOUSE MODEL OF ALZHEIMER'S DISEASE. , 2014, 10, P315-P315.		0
63	Lentiviral Vectors in Huntington's Disease Research and Therapy. <i>Neuromethods</i> , 2014, , 193-220.	0.3	1
64	RNA Interference Mitigates Motor and Neuropathological Deficits in a Cerebellar Mouse Model of Machado-Joseph Disease. <i>PLoS ONE</i> , 2014, 9, e100086.	2.5	33
65	O1-07-05: In vivo tau spreading relies on the transsynaptic transfer of soluble wild-type tau species. , 2013, 9, P142-P142.		0
66	Beclin 1 mitigates motor and neuropathological deficits in genetic mouse models of Machado-Joseph disease. <i>Brain</i> , 2013, 136, 2173-2188.	7.6	86
67	Overexpression of Mutant Ataxin-3 in Mouse Cerebellum Induces Ataxia and Cerebellar Neuropathology. <i>Cerebellum</i> , 2013, 12, 441-455.	2.5	24
68	Lentiviral-Mediated Gene Transfer of siRNAs for the Treatment of Huntington's Disease. <i>Methods in Molecular Biology</i> , 2013, 1010, 95-109.	0.9	4
69	Lentiviral Delivery of the Human Wild-type Tau Protein Mediates a Slow and Progressive Neurodegenerative Tau Pathology in the Rat Brain. <i>Molecular Therapy</i> , 2013, 21, 1358-1368.	8.2	31
70	BDNF overexpression in mouse hippocampal astrocytes promotes local neurogenesis and elicits anxiolytic-like activities. <i>Translational Psychiatry</i> , 2013, 3, e253-e253.	4.8	189
71	A role of mitochondrial complex II defects in genetic models of Huntington's disease expressing N-terminal fragments of mutant huntingtin. <i>Human Molecular Genetics</i> , 2013, 22, 3869-3882.	2.9	93
72	Silencing Mutant Ataxin-3 Rescues Motor Deficits and Neuropathology in Machado-Joseph Disease Transgenic Mice. <i>PLoS ONE</i> , 2013, 8, e52396.	2.5	104

#	ARTICLE	IF	CITATIONS
73	Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. <i>Frontiers in Cellular Neuroscience</i> , 2013, 7, 106.	3.7	44
74	Lentiviral Vectors: A Powerful Tool to Target Astrocytes In Vivo. <i>Current Drug Targets</i> , 2013, 14, 1336-1346.	2.1	20
75	Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells. <i>Human Molecular Genetics</i> , 2012, 21, 3883-3895.	2.9	82
76	B04â€¦AMPK activation alleviates phenotypes associated to the early phases of mutant polyQ cytotoxicity. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, A6.3-A7.	1.9	0
77	Capucin does not modify the toxicity of a mutant Huntingtin fragment in vivo. <i>Neurobiology of Aging</i> , 2012, 33, 1845.e5-1845.e6.	3.1	7
78	Calpastatin-mediated inhibition of calpains in the mouse brain prevents mutant ataxin 3 proteolysis, nuclear localization and aggregation, relieving Machado-Joseph disease. <i>Brain</i> , 2012, 135, 2428-2439.	7.6	98
79	Viral-mediated overexpression of mutant huntingtin to model HD in various species. <i>Neurobiology of Disease</i> , 2012, 48, 202-211.	4.4	15
80	Restricted Transgene Expression in the Brain with Cell-Type Specific Neuronal Promoters. <i>Human Gene Therapy Methods</i> , 2012, 23, 242-254.	2.1	36
81	Overexpression of the autophagic beclin-1 protein clears mutant ataxin-3 and alleviates Machado-Joseph disease. <i>Brain</i> , 2011, 134, 1400-1415.	7.6	171
82	Mitogen- and stress-activated protein kinase 1-induced neuroprotection in Huntington's disease: role on chromatin remodeling at the PGC-1-alpha promoter. <i>Human Molecular Genetics</i> , 2011, 20, 2422-2434.	2.9	50
83	Nuclear Factor Erythroid 2-Related Factor 2 Facilitates Neuronal Glutathione Synthesis by Upregulating Neuronal Excitatory Amino Acid Transporter 3 Expression. <i>Journal of Neuroscience</i> , 2011, 31, 7392-7401.	3.6	86
84	A09â€¦Characterisation of AMPK activity in models of Huntington's disease pathogenesis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, A3.3-A3.	1.9	0
85	In vivo expression of polyglutamine-expanded huntingtin by mouse striatal astrocytes impairs glutamate transport: a correlation with Huntington's disease subjects. <i>Human Molecular Genetics</i> , 2010, 19, 3053-3067.	2.9	282
86	Silencing ataxin-3 mitigates degeneration in a rat model of Machado-Joseph disease: no role for wild-type ataxin-3?. <i>Human Molecular Genetics</i> , 2010, 19, 2380-2394.	2.9	96
87	Mitochondria in Huntington's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2010, 1802, 52-61.	3.8	235
88	Normal Aging Modulates the Neurotoxicity of Mutant Huntingtin. <i>PLoS ONE</i> , 2009, 4, e4637.	2.5	29
89	Human Î±-Iduronidase Gene Transfer Mediated by Adeno-Associated Virus Types 1, 2, and 5 in the Brain of Nonhuman Primates: Vector Diffusion and Biodistribution. <i>Human Gene Therapy</i> , 2009, 20, 350-360.	2.7	57
90	Positron Emission Tomography Imaging Demonstrates Correlation between Behavioral Recovery and Correction of Dopamine Neurotransmission after Gene Therapy. <i>Journal of Neuroscience</i> , 2009, 29, 1544-1553.	3.6	32

#	ARTICLE	IF	CITATIONS
91	Sustained effects of nonallele-specific <i>Huntingtin</i> silencing. <i>Annals of Neurology</i> , 2009, 65, 276-285.	5.3	196
92	Engineered lentiviral vector targeting astrocytes <i>In vivo</i> . <i>Glia</i> , 2009, 57, 667-679.	4.9	136
93	Diminished hippocalcalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons. <i>Journal of Neurochemistry</i> , 2009, 111, 460-472.	3.9	27
94	Implication of the JNK pathway in a rat model of Huntington's disease. <i>Experimental Neurology</i> , 2009, 215, 191-200.	4.1	63
95	Viral Vectors for in Vivo Gene Transfer. , 2009, , 1069-1096.		0
96	Haloperidol protects striatal neurons from dysfunction induced by mutated huntingtin in vivo. <i>Neurobiology of Disease</i> , 2008, 29, 22-29.	4.4	58
97	Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant huntingtin through the regulation of mitochondrial complex II. <i>Human Molecular Genetics</i> , 2008, 17, 1446-1456.	2.9	66
98	Striatal and nigral pathology in a lentiviral rat model of Machado-Joseph disease. <i>Human Molecular Genetics</i> , 2008, 17, 2071-2083.	2.9	78
99	Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry. <i>Journal of Neuroscience</i> , 2008, 28, 9723-9731.	3.6	89
100	Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders. <i>Current Gene Therapy</i> , 2008, 8, 461-473.	2.0	139
101	Human and simian immunodeficiency viruses deregulate early hematopoiesis through a Nef/PPAR $\beta$ /STAT5 signaling pathway in macaques. <i>Journal of Clinical Investigation</i> , 2008, 118, 1765-75.	8.2	63
102	Allele-Specific RNA Silencing of Mutant Ataxin-3 Mediates Neuroprotection in a Rat Model of Machado-Joseph Disease. <i>PLoS ONE</i> , 2008, 3, e3341.	2.5	141
103	Gene Transfer Techniques for the Delivery of GDNF in Parkinson's Disease. <i>Novartis Foundation Symposium</i> , 2008, 231, 202-219.	1.1	10
104	Neuroprotection by Hsp104 and Hsp27 in Lentiviral-based Rat Models of Huntington's Disease. <i>Molecular Therapy</i> , 2007, 15, 903-911.	8.2	135
105	Activation of Astrocytes by CNTF Induces Metabolic Plasticity and Increases Resistance to Metabolic Insults. <i>Journal of Neuroscience</i> , 2007, 27, 7094-7104.	3.6	103
106	Expression of Mutated Huntingtin Fragment in the Putamen Is Sufficient to Produce Abnormal Movement in Non-human Primates. <i>Molecular Therapy</i> , 2007, 15, 1444-1451.	8.2	83
107	Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts. <i>Journal of the Neurological Sciences</i> , 2007, 255, 7-16.	0.6	21
108	Transplants of CNTF-producing Cells for the Treatment of Huntington's Disease. , 2007, , 385-398.		2



#	ARTICLE	IF	CITATIONS
109	Lentivirus-mediated expression of glutathione peroxidase: Neuroprotection in murine models of Parkinson's disease. <i>Neurobiology of Disease</i> , 2006, 21, 29-34.	4.4	69
110	Ciliary Neurotrophic Factor Activates Astrocytes, Redistributes Their Glutamate Transporters GLAST and GLT-1 to Raft Microdomains, and Improves Glutamate Handling In Vivo. <i>Journal of Neuroscience</i> , 2006, 26, 5978-5989.	3.6	79
111	Involvement of Mitochondrial Complex II Defects in Neuronal Death Produced by N-Terminus Fragment of Mutated Huntingtin. <i>Molecular Biology of the Cell</i> , 2006, 17, 1652-1663.	2.1	217
112	CA150 Expression Delays Striatal Cell Death in Overexpression and Knock-In Conditions for Mutant Huntingtin Neurotoxicity. <i>Journal of Neuroscience</i> , 2006, 26, 4649-4659.	3.6	48
113	Inhibition of Calcineurin by FK506 Protects against Polyglutamine-Huntingtin Toxicity through an Increase of Huntingtin Phosphorylation at S421. <i>Journal of Neuroscience</i> , 2006, 26, 1635-1645.	3.6	121
114	Akt is altered in an animal model of Huntington's disease and in patients. <i>European Journal of Neuroscience</i> , 2005, 21, 1478-1488.	2.6	156
115	Viral vectors as tools to model and treat neurodegenerative disorders. <i>Journal of Gene Medicine</i> , 2005, 7, 530-539.	2.8	46
116	Minocycline in phenotypic models of Huntington's disease. <i>Neurobiology of Disease</i> , 2005, 18, 206-217.	4.4	52
117	Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment. <i>Neurobiology of Disease</i> , 2005, 20, 785-798.	4.4	74
118	Lentiviral-Mediated Gene Transfer to Model Triplet Repeat Disorders. , 2004, 277, 199-214.		8
119	Survival of Encapsulated Human Primary Fibroblasts and Erythropoietin Expression Under Xenogeneic Conditions. <i>Human Gene Therapy</i> , 2004, 15, 669-680.	2.7	34
120	Neuroprotective Gene Therapy for Huntington's Disease, Using Polymer-Encapsulated Cells Engineered to Secrete Human Ciliary Neurotrophic Factor: Results of a Phase I Study. <i>Human Gene Therapy</i> , 2004, 15, 968-975.	2.7	222
121	Long-term lentiviral-mediated expression of ciliary neurotrophic factor in the striatum of Huntington's disease transgenic mice. <i>Experimental Neurology</i> , 2004, 185, 26-35.	4.1	54
122	Local GDNF expression mediated by lentiviral vector protects facial nerve motoneurons but not spinal motoneurons in SOD1G93A transgenic mice. <i>Neurobiology of Disease</i> , 2004, 16, 139-149.	4.4	47
123	Encapsulated GDNF-producing C2C12 cells for Parkinson's disease: a pre-clinical study in chronic MPTP-treated baboons. <i>Neurobiology of Disease</i> , 2004, 16, 428-439.	4.4	87
124	Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease. <i>Neurobiology of Disease</i> , 2004, 17, 283-289.	4.4	118
125	Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. <i>Journal of Controlled Release</i> , 2003, 87, 107-115.	9.9	47
126	Optimization of human erythropoietin secretion from MLV-infected human primary fibroblasts used for encapsulated cell therapy. <i>Journal of Gene Medicine</i> , 2003, 5, 246-257.	2.8	20



#	ARTICLE	IF	CITATIONS
127	French gene therapy group reports on the adverse event in a clinical trial of gene therapy for X-linked severe combined immune deficiency (X-SCID). <i>Journal of Gene Medicine</i> , 2003, 5, 82-84.	2.8	30
128	Presence of Gal-1,3Gal epitope on xenogeneic lines: implications for cellular gene therapy based on the encapsulation technology. <i>Xenotransplantation</i> , 2003, 10, 204-213.	2.8	8
129	Activity analysis of housekeeping promoters using self-inactivating lentiviral vector delivery into the mouse retina. <i>Gene Therapy</i> , 2003, 10, 818-821.	4.5	70
130	Multiply Attenuated, Self-Inactivating Lentiviral Vectors Efficiently Deliver and Express Genes for Extended Periods of Time in Adult Rat Cardiomyocytes In Vivo. <i>Circulation</i> , 2003, 107, 2375-2382.	1.6	82
131	Delivery of Ciliary Neurotrophic Factor via Lentiviral-Mediated Transfer Protects Axotomized Retinal Ganglion Cells for an Extended Period of Time. <i>Human Gene Therapy</i> , 2003, 14, 103-115.	2.7	101
132	Early and reversible neuropathology induced by tetracycline-regulated lentiviral overexpression of mutant huntingtin in rat striatum. <i>Human Molecular Genetics</i> , 2003, 12, 2827-2836.	2.9	75
133	Î-Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 10813-10818.	7.1	488
134	Long-Term Doxycycline-Regulated Secretion of Erythropoietin by Encapsulated Myoblasts. <i>Molecular Therapy</i> , 2002, 6, 155-161.	8.2	35
135	Dose-Dependent Neuroprotective Effect of Ciliary Neurotrophic Factor Delivered via Tetracycline-Regulated Lentiviral Vectors in the Quinolinic Acid Rat Model of Huntington's Disease. <i>Human Gene Therapy</i> , 2002, 13, 1981-1990.	2.7	109
136	Lentiviral-Mediated RNA Interference. <i>Human Gene Therapy</i> , 2002, 13, 2197-2201.	2.7	273
137	Neurospheres modified to produce glial cell line-derived neurotrophic factor increase the survival of transplanted dopamine neurons. <i>Journal of Neuroscience Research</i> , 2002, 69, 955-965.	2.9	117
138	Seizure Suppression by Adenosine-Releasing Cells Is Independent of Seizure Frequency. <i>Epilepsia</i> , 2002, 43, 788-796.	5.1	59
139	Delivery of erythropoietin by encapsulated myoblasts in a genetic model of severe anemia. <i>Kidney International</i> , 2002, 62, 1395-1401.	5.2	32
140	Lentiviruses as Vectors for CNS Diseases. <i>Current Topics in Microbiology and Immunology</i> , 2002, 261, 191-209.	1.1	32
141	Lentiviral-Mediated Delivery of Mutant Huntingtin in the Striatum of Rats Induces a Selective Neuropathology Modulated by Polyglutamine Repeat Size, Huntingtin Expression Levels, and Protein Length. <i>Journal of Neuroscience</i> , 2002, 22, 3473-3483.	3.6	184
142	Lentivirally Delivered Glial Cell Line-Derived Neurotrophic Factor Increases the Number of Striatal Dopaminergic Neurons in Primate Models of Nigrostriatal Degeneration. <i>Journal of Neuroscience</i> , 2002, 22, 4942-4954.	3.6	187
143	Isolation of Multipotent Neural Precursors Residing in the Cortex of the Adult Human Brain. <i>Experimental Neurology</i> , 2001, 170, 48-62.	4.1	274
144	Gene Transfer into Neurons from Hippocampal Slices: Comparison of Recombinant Semliki Forest Virus, Adenovirus, Adeno-Associated Virus, Lentivirus, and Measles Virus. <i>Molecular and Cellular Neurosciences</i> , 2001, 17, 855-871.	2.2	125

#	ARTICLE	IF	CITATIONS
145	Neuroprotective Effect of a CNTF-Expressing Lentiviral Vector in the Quinolinic Acid Rat Model of Huntington's Disease. <i>Neurobiology of Disease</i> , 2001, 8, 433-446.	4.4	150
146	Viral vector-mediated gene therapy for Parkinson's disease. <i>Clinical Neuroscience Research</i> , 2001, 1, 496-506.	0.8	8
147	Neuroprotective effect of interleukin-6 and IL6/IL6R chimera in the quinolinic acid rat model of Huntington's syndrome. <i>European Journal of Neuroscience</i> , 2001, 14, 1753-1761.	2.6	44
148	Grafts of adenosine-releasing cells suppress seizures in kindling epilepsy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 7611-7616.	7.1	196
149	Complete and Long-Term Rescue of Lesioned Adult Motoneurons by Lentiviral-Mediated Expression of Glial Cell Line-Derived Neurotrophic Factor in the Facial Nucleus. <i>Journal of Neuroscience</i> , 2000, 20, 5587-5593.	3.6	170
150	Restoration of Cognitive and Motor Functions by Ciliary Neurotrophic Factor in a Primate Model of Huntington's Disease. <i>Human Gene Therapy</i> , 2000, 11, 1177-1188.	2.7	138
151	Neuroprotective Gene Therapy for Huntington's Disease Using a Polymer Encapsulated BHK Cell Line Engineered to Secrete Human CNTF. <i>Human Gene Therapy</i> , 2000, 11, 1723-1729.	2.7	154
152	Lentiviral Vectors as a Gene Delivery System in the Mouse Midbrain: Cellular and Behavioral Improvements in a 6-OHDA Model of Parkinson's Disease Using GDNF. <i>Experimental Neurology</i> , 2000, 164, 15-24.	4.1	167
153	Neurodegeneration Prevented by Lentiviral Vector Delivery of GDNF in Primate Models of Parkinson's Disease. <i>Science</i> , 2000, 290, 767-773.	12.6	1,201
154	Self-Inactivating Lentiviral Vectors with Enhanced Transgene Expression as Potential Gene Transfer System in Parkinson's Disease. <i>Human Gene Therapy</i> , 2000, 11, 179-190.	2.7	276
155	Efficient Gene Transfer and Expression of Biologically Active Glial Cell Line-Derived Neurotrophic Factor in Rat Motoneurons Transduced with Lentiviral Vectors. <i>Journal of Neurochemistry</i> , 2000, 74, 1820-1828.	3.9	28
156	Cellular xenotransplantation. <i>Nature Medicine</i> , 1999, 5, 852-852.	30.7	9
157	Improvement of mouse $\beta$ -thalassemia upon erythropoietin delivery by encapsulated myoblasts. <i>Gene Therapy</i> , 1999, 6, 157-161.	4.5	48
158	Lentiviral Gene Transfer to the Nonhuman Primate Brain. <i>Experimental Neurology</i> , 1999, 160, 1-16.	4.1	186
159	Continuous delivery of human and mouse erythropoietin in mice by genetically engineered polymer encapsulated myoblasts. <i>Gene Therapy</i> , 1998, 5, 1014-1022.	4.5	76
160	A Gene Therapy Approach to Regulated Delivery of Erythropoietin as a Function of Oxygen Tension. <i>Human Gene Therapy</i> , 1997, 8, 1881-1889.	2.7	88
161	A Gene Therapy Approach for the Treatment of Amyotrophic Lateral Sclerosis and Parkinson's Disease. <i>Advances in Pharmacology</i> , 1997, 42, 929-931.	2.0	2
162	Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. <i>Cell Transplantation</i> , 1996, 5, 577-587.	2.5	35

#	ARTICLE	IF	CITATIONS
163	Central Nervous System Delivery of Recombinant Ciliary Neurotrophic Factor by Polymer Encapsulated Differentiated C <sub>2</sub> Myoblasts. Human Gene Therapy, 1996, 7, 2135-2146.	2.7	78
164	Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nature Medicine, 1996, 2, 696-699.	30.7	449
165	Gene Therapy for Amyotrophic Lateral Sclerosis (ALS) Using a Polymer Encapsulated Xenogenic Cell Line Engineered to Secrete hCNTF. Lausanne University Medical School, Lausanne, Switzerland. Human Gene Therapy, 1996, 7, 851-860.	2.7	108
166	Rescue of motoneurons from axotomy-induced cell death by polymer encapsulated cells genetically engineered to release CNTF. Cell Transplantation, 1996, 5, 577-87.	2.5	2
167	Encapsulation of neurotrophic factor-releasing cells for the treatment of neurodegenerative diseases. Restorative Neurology and Neuroscience, 1995, 8, 65-66.	0.7	6
168	Fatty Acids Regulate Thy-1 Antigen mRNA Stability in T Lymphocyte Precursors. FEBS Journal, 1995, 231, 687-696.	0.2	8
169	Minimal membrane and secreted 1/4 poly(A) signals specify developmentally-regulated immunoglobulin heavy chain mRNA ratios without RNA splicing. Molecular Immunology, 1994, 31, 563-566.	2.2	0
170	Membrane 1/4 poly(A) signal and 3' flanking sequences function as a transcription terminator for immunoglobulin-encoding genes. Gene, 1992, 122, 297-304.	2.2	3
171	Multi-level regulation of Thy-1 antigen expression in mouse T lymphomas. Immunogenetics, 1992, 35, 126-30.	2.4	8
172	EVALUATION OF SOMATIC CELL VARIANTS DEFICIENT IN GLYCOSYLPHOSPHATIDYL-INOSITOL ANCHORING AS CANDIDATES FOR GENETIC CORRECTION. , 1992, , 197-210.		0
173	Evaluation of somatic cell variants deficient in glycosylphosphatidyl-inositol anchoring as candidates for genetic correction. Cell Biology International Reports, 1991, 15, 1051-1064.	0.6	5
174	Translocation of the yeast Dolichol-phosphate-mannose synthase into microsomal membranes. Biochemical and Biophysical Research Communications, 1991, 174, 1337-1342.	2.1	6
175	Isolation from mouse fibroblasts of a cDNA encoding a new form of the fibroblast growth factor receptor (flg). Biochemical and Biophysical Research Communications, 1991, 178, 8-15.	2.1	12
176	Restricted transgene expression in the brain with cell-type specific neuronal promoters. Human Gene Therapy Methods, 0, , 121017063203000.	2.1	3